Two Key Elements to Musks $54.20 a Share Offer for Twitter



Will the Twitter Board Consider Musk’s Offer as Best for Shareholders?

 

By now you’re aware that Elon Musk has offered $43 billion for every share of Twitter (TWTR). His offer is to buy the company outright and run it as a private company.

The offer is not, according to the filing, a negotiation. Management will have to make a recommendation to the Board of Directors which will then be expected to decide as a fiduciary and act in the shareholder’s best interest. A counter offer may end the deal. In Musk’s words, “I am not playing the back and forth game.” He also said, “It’s a high price and your shareholder’s will love it.”

The richest man alive also made it clear that if the offer is declined, the 9.2% stake he owns may go up for sale. This could have the opposite impact on the stock price.

 

Elon’s Notes to Bret Taylor, Chairman of Twitter’s Board

 

Source: SEC.Gov
Amendment #2 to 13D Filing

 

Source: SEC.Gov
Amendment #2 to 13D Filing

 

In the filing Mr. Musk includes his text and follow-up note to Twitter’s Board chairman. The communications are peppered with language that includes “free speech” and “societal imperative.” It is clear that the offer is designed to either cause the board to accept, as it is a high relative price for the company, or embarrass the company as it would seem akin to saying they don’t have his concerns about society.

 

The Price

$43 Billion is the approximate valuation of Twitter as per Musk’s offer. This should help avoid trouble and concerns of stock manipulation from the regulators as it represents a 54% premium over the company’s value the day before he began investing in it.

The price of 54.20 per share may reflect Musk’s sense of humor. The number 420 is code for smoking marijuana. Musk has used the number before to amuse
his girlfriend
and others that are aware of this.

Next week, April 20 is celebrated as the high holiday, National Weed Day, perhaps he is looking to settle this by then.

Paul Hoffman

Managing Editor, Channelchek

 

 

Stay up to date. Follow us:

 

Release – Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference



Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the NobleCon18—Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21, 2022 at 9:30 a.m. Eastern Time. The conference is being held at the Hard Rock Hotel & Casino in Hollywood, Fla.

A video webcast of the presentation will be available the following day on the Company’s https://www.channelchek.com/, as well as at the Noble Capital Markets’ Conference website and on the Channelchek website. The webcast will be archived for 90 days following the event.

About Noble Capital Markets, Inc.
Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984. As a FINRA and SEC licensed broker dealer, Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the past decade. In 2018, Noble launched Channelchek—an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public for free without a subscription.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Rates Rubles and Gold



With the Russia-Ukraine War, Gold’s Safe-Haven Status Lasts

 

While several asset classes have suffered immense stress in recent weeks, precious metals (PMs) have remained relatively elevated. Moreover, concerns have arisen that since the Russian central bank pegged the ruble to gold, it helps uplift the yellow metal.

For context, the Russian central bank announced on Mar. 25 that it would pay 5,000 rubles ($52) per gram of gold. This allowed the USD/RUB to garner an exchange rate of ~96.15 (5,000/52). However, the important point is that the policy was aimed at supporting the ruble, not the PMs.

To explain, when Russia invaded Ukraine, NATO responded with seismic sanctions. As a result, the USD/RUB rallied to an all-time high of 121.21. However, the threats worked perfectly for Russia, as the USD/RUB is now at ~79.68 and lower than the 85.28 recorded pre-invasion. Furthermore, Russian President Vladimir Putin attempted the same feat when he said that all Russian gas exports would need to be paid for in rubles.

A Reuters article stated:

“Putin’s order to charge ‘unfriendly’ countries in rubles for Russian gas boosted the Russian currency after it plunged to all-time lows when the West imposed sweeping sanctions on Moscow for its invasion of Ukraine. European gas prices also rocketed up.”

However, with the ruble strengthening materially in recent weeks, the policy is no longer needed.

Please see below:

 

 

Likewise, it’s the same story for the PMs. After announcing the fixed peg on Mar. 25, the Kremlin scrapped that policy on Apr. 7, since the ruble is strong enough and doesn’t need any indirect support.

Please see below:

 

 

Furthermore, the Russian central bank cited a “significant change in market conditions” for reversing the policy. In a nutshell: since the ruble is stronger than it was before the invasion, the currency impact of sanctions is immaterial. Therefore, the central bank is happy to let the ruble float.

Please see below:

 

 

All in all, the moves made by the Russian central bank were designed to support the ruble. When a currency plunges, the FX-adjusted cost of imports skyrockets. As such, sanctions would cripple growth, inflation would rage, and the Russian economy would suffer stagflation on steroids. However, by stabilizing the currency, Russia solves half of the problem. Thus, while the recent developments may seem like they uplifted the PMs, they’re largely immaterial from a medium-term perspective.

More importantly, the PMs’ domestic fundamental outlooks continue to deteriorate. For example, the U.S. 10-Year real yield hit a new 2022 high of -0.12% on Apr. 11 and closed at -0.13% on Apr. 12. Moreover, while momentum keeps the yellow metal uplifted, history shows that the current gold price is unsustainable.

 

 

Still a Momentum Trade

To explain, the gold line above tracks the price tallied by the World Gold Council, while the red line above tracks the inverted U.S. 10-Year real yield. For context, inverted means that the latter’s scale is flipped upside down and that a rising red line represents a falling U.S. 10-Year real yield, while a falling red line represents a rising U.S. 10-Year real yield.

Moreover, I wrote on Apr. 11 that gold and the U.S. 10-Year real yield have a daily correlation of -0.92 since 2007. Therefore, we must ignore 15+ years of historical data to assume that gold’s best days lie ahead.

To that point, the famous quote from John Maynard Keynes is relevant here. He said that “markets can stay irrational longer than you can stay solvent.” In a nutshell: the price action can make investors second-guess themselves, even when the data supports the opposite conclusion. Furthermore, if you analyze the arrows above, you can see that investors’ optimism helped gold outperform the U.S. 10-Year real yield in 2011, while investors’ pessimism helped gold underperform the U.S. 10-Year real yield in 2015.

As a result, sentiment rules the day in the short term, and the algorithms move in whichever direction the wind is blowing. Therefore, we find ourselves in that situation now. With the Russia-Ukraine conflict increasing gold’s geopolitical appeal, safe-haven momentum remains ripe. In addition, another 2022 high in the headline Consumer Price Index (CPI) also increases gold’s inflation-hedge appeal. For context, the metric increased by 8.5% year-over-year (YoY) on Apr. 12.

 

 

However, investors are short-sighted about the medium-term implications. While conventional wisdom implies that abnormally high inflation is bullish for the PMs, the reality is that pricing pressures awaken the Fed. Since positive real yields are essential to curb inflation, the Fed has to tighten financial conditions to achieve its goal.

To explain, I wrote on Apr. 5:

I warned throughout 2021 that a hawkish Fed and tighter financial conditions are bearish for the PMs. And while the fundamental expectation worked perfectly before the Russia-Ukraine crises erupted, the medium-term thesis is clearer now than it was then.

Please see below:

 

 

To explain, the orange line above tracks the number of rate hikes priced in by the futures market, while the blue line above tracks Goldman Sachs’ Financial Conditions Index (FCI). If you analyze the movement of the former, futures traders expect roughly nine rate hikes by the Fed in 2022.

However, if you focus your attention on the right side of the chart, you can see that the FCI has declined materially from its highs. Therefore, financial conditions are easier now than they were before the March FOMC meeting. However, the Fed needs to tighten financial conditions to calm inflation. But since market participants are not listening, Chairman Jerome Powell needs to amplify his hawkish rhetoric until the message hits home.

 

Think about it: if looser financial conditions are used to stimulate economic growth and inflation, how can the Fed calm the pressures without reversing the situation? Moreover, please remember that the current policy stance contributed to 8%+ annualized inflation. Thus, it’s unrealistic to materially reduce inflation from 8% to 2% without the Fed materially shifting the liquidity dynamics. Therefore, investors’ optimism will likely reverse sharply over the medium term.

To that point, while the implications of a higher FCI and higher real yields take time to play out, the Fed has upped the hawkish ante in recent days. In the process, both the bond and the stock market have changed their tones. Therefore, commodities like the PMs will likely be the last shoe to drop.

For additional context, I wrote on Feb. 2:

 

 

If you analyze the right side of the chart, you can see that the FCI has surpassed its pre-COVID-19 high (January 2020). Moreover, the FCI bottomed in January 2021 and has been seeking higher ground ever since. In the process, it’s no coincidence that the PMs have suffered mightily since January 2021. Furthermore, with the Fed poised to raise interest rates at its March monetary policy meeting, the FCI should continue its ascent. As a result, the PMs’ relief rallies should fall flat like in 2021.

Likewise, while the USD Index has come down from its recent high, it’s no coincidence that the dollar basket bottomed with the FCI in January 2021 and hit a new high with the FCI in January 2022. Thus, while the recent consolidation may seem troubling, the medium-term fundamentals supporting the greenback remain robust.

Thus, while the USD Index has surpassed 100 and reflects the fundamental reality of a higher FCI and higher real yields, the PMs do not. However, the PMs are in la la land since the FCI is now at its highest level since the global financial crisis (GFC).

Please see below:

 

 

Also noteworthy, the FCI made quick work of the March 2020 high from the first chart above. Again, Fed officials know that higher real yields and tighter financial conditions are needed to curb inflation. That’s why they keep amplifying their hawkish message and warning investors of what lies ahead. However, with commodities refusing to accept this reality, they’ll likely be the hardest-hit once the Fed’s rate hike cycle truly unfolds.

Speaking of which, Fed Governor Lael Brainard said on Apr. 12: “Inflation is too high, and getting inflation down is going to be our most important task.”

She added: “I think there’s quite a bit of capacity for labor demand to moderate among businesses by actually reducing job openings without necessitating high levels of layoffs.” As a result, she’s telling you that Fed officials will make it their mission to slow down the U.S. economy.

With phrases like “capacity for labor demand to moderate” and “reducing job openings” code for what has to happen to calm wage inflation, the prospect of a dovish 180 is slim to none. As such, this is bullish for real yields and bearish for the PMs.

More importantly, notice her use of that all-important buzzword.

 

 

Moreover, where do you think she got it?

 

 

For context, Powell said that on Mar. 21. The bottom line? It’s remarkable how the PMs’ fundamentals can deteriorate so rapidly while sentiment remains so optimistic. However, while the Russia-Ukraine conflict keeps the momentum alive, it’s likely a long way down when the war premiums unravel.

Moreover, while real yields and financial conditions imply much lower prices for the PMs, they still have plenty of room to run over the medium term. As a result, while the permabulls may feel invincible, the fundamentals that drove the PMs’ performance over the last 15+ years couldn’t be more bearish.

In conclusion, the PMs rallied on Apr. 12, as momentum runs high across the commodity complex. However, investors either fail to foresee the medium-term consequences of the Fed’s rate hike cycle, or they simply don’t care. Either way, reality should re-emerge over the next few months, and once sentiment shifts, the PMs’ lack of fundamental foundations should result in profound drawdowns.

Thank you for reading our free analysis today. Please note that the above is just a small fraction of the full analyses that our subscribers enjoy on a regular basis. They include multiple premium details such as the interim targets for gold and mining stocks that could be reached in the next few weeks. We invite you to subscribe now and read today’s issue right away.

 

About the Author:  
Przemyslaw Radomski, CFA  (PR) writes for and publishes articles that underscore his disposition of being passionately curious about markets behavior. He uses his statistical and financial background to question the common views and profit on the misconceptions.

 

Suggested Reading



Precious Metals Seem to be Ignoring the Fed’s message



The SPAC Advantage in a Volatile or Bear Market





How do Gold Royalty Companies Work?



Metals & Mining First Quarter 2022 Review and Outlook

 

Source

https://www.sunshineprofits.com/

 

Stay up to date. Follow us:

 

Release – FAT Brands Quick-Service Division Continues Strong Growth Momentum



FAT Brands’ Quick-Service Division Continues Strong Growth Momentum, Signing Development Agreements Totaling Over 50 New Stores

Research, News, and Market Data on FAT Brands

 

Global Franchise Group, Now FAT Brands’ Quick-Service Division, Experiences Strong Franchisee Demand Following June 2021 Acquisition

LOS ANGELES, April 13, 2022 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Round Table Pizza, Great American Cookies, Marble Slab Creamery, and 14 other restaurant concepts, announces its Quick-Service Division has signed 20 new development deals, totaling over 50 additional units, following the acquisition of Global Franchise Group in June 2021. The acquisition marked FAT Brands’ foray into both the snack and pizza categories, adding the following brands: Round Table Pizza, Great American Cookies, Marble Slab Creamery, Hot Dog on a Stick and Pretzelmaker.

Since the formation of the Quick-Service Division, composed of the brands from the Global Franchise Group acquisition, demand has been high for new franchises, in particular, amongst existing franchisees. The Great American Cookies & Marble Slab Creamery co-branded restaurant model continues to be attractive to new and existing franchisees alike with new deals in areas including Nashville, Tenn., Houston and Shreveport, La. Round Table Pizza is also deepening its presence in California, with agreements signed for nine new locations to open throughout the state in the coming years. Additional deals were also signed for Great American Cookies, Marble Slab Creamery, Hot Dog on a Stick and Pretzelmaker. In total, there are over 150 units in the pipeline in the Quick-Service Division with over 30 locations set to open their doors in 2022.

“While the pandemic has certainly impacted the restaurant space, we are so fortunate to have a deep store pipeline in addition to solid same-store-sales growth,” said Jenn Johnston, President of FAT Brands’ Quick-Service Division. “In the fourth quarter of 2021, same-store-sales within the division were up 10.6% in comparison to 2019 and up 16.1% in comparison to 2020. Since joining FAT Brands, we have increased our scale, offered franchisees access to new services, and have formed new synergies at both the brand and corporate level.”

“The Quick-Service brands have been a strong addition to the FAT Brands portfolio,” said Taylor Wiederhorn, Chief Development Officer of FAT Brands. “In just nine months we have made incredible traction in not only integrating the brands, but also in signing new development deals. We look forward to continuing to broaden the division’s presence on a global level in the years to come.”

For more information on FAT Brands, please visit www.fatbrands.com.

About FAT (Fresh. Authentic. Tasty.) Brands
FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing and performance of new store openings. Forward-looking statements reflect expectations of FAT Brands Inc. (“we”, “our” or the “Company”) concerning the future and are subject to significant business, economic and competitive risks, uncertainties and contingencies, including but not limited to uncertainties surrounding the severity, duration and effects of the COVID-19 pandemic. These factors are difficult to predict and beyond our control, and could cause our actual results to differ materially from those expressed or implied in such forward-looking statements. We refer you to the documents that we file from time to time with the Securities and Exchange Commission, such as our reports on Form 10-K, Form 10-Q and Form 8-K, for a discussion of these and other factors. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

MEDIA CONTACT:
Erin Mandzik, FAT Brands
emandzik@fatbrands.com
860-212-6509

Release – Comstock Acquires Industrial Battery Storage Property



Comstock Acquires Industrial Battery Storage Property

Research, News, and Market Data on Comstock Mining

 

VIRGINIA CITY, NEVADA, April 13, 2022 – Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced it has a definitive agreement to acquire the Haywood quarry and industrial property (the “Haywood” or “Property) from Decommissioning Services LLC for a total of $2.1 million in cash and stock. The Haywood property represents approximately 190 industrial acres in Lyon County, Nevada, and part of the one of the largest industrial parks in Lyon County. The Property has power, water and immediate highway access.

The Company plans to immediately employ a portion of the property for used lithium-ion battery (“LIB”) storage, to support the battery metal recycling operations of LINICO Corporation (“LiNiCo”), one of Comstock’s renewable energy subsidiaries. The property will receive, sort, and store waste LIBs and has immediate and easy access to US 50 which simplifies as-needed transportation to LiNiCo’s battery metal crushing, separating and processing facility located in the Tahoe-Reno Industrial Center, right off US 50, in Storey County, NV.

“This site is a key acquisition, supporting Comstock’s transformation into a renewable energy company,” stated Mr. Corrado De Gasperis, Comstock’s Executive Chairman and CEO. “It requires minimal site preparation and permitting to become a critical link in the system necessary for LiNiCo to operate at maximum throughput.”

The property originally (and currently) hosted both gold and aggregate mineral resources and mining operations.  The property is strategically located and contiguous to the Company’s mineral properties in Lyon County.

Conventional recycling processes suffer from high lithium losses. Once the pilot crushing and separating system is operating later this year, the Company plans on extracting lithium immediately after crushing and conditioning for market leading yields that maximize lithium recovery for reuse in these electrification products.

Securing this large industrial storage site complements the Nevada-based platform for a fully integrated series of operations where the Company is currently permitting and building both pilot and commercial scale facilities for lithium-ion batteries recycling and is preparing to commence operations later this year. LiNiCo’s near term plans include efficiently crushing and separating LIBs and producing pure black mass, rich in critical battery metals including lithium, nickel, cobalt, and graphite, and then extracting substantially all of the lithium first. 

“LiNiCo’s ‘black mass’ powders are projecting highly concentrated materials with exceptionally high purities, giving us unprecedented optionality to work with multiple refining partners to maximize recovery of cobalt, nickel, copper, and other battery metals,” continued Mr. De Gasperis, “our lithium extraction developments will activate our “lithium first” strategy that enables profitability at relative low volumes of operation and real growth.

About Comstock 

Comstock (NYSE: LODE) innovates technologies that enable systemic decarbonization and circularity by efficiently converting under-utilized waste and renewable natural resources into fuels and electrification products that contribute to balancing global uses and emissions of carbon. Comstock plans to achieve extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, commercializing complimentary process solutions and related services, and licensing selected technologies to strategic partners.

To learn more, please visit www.comstock.inc.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future changes in our research and development; and future prices and sales of, and demand for, our products and services. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related call or discussion constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

  Contact information:    
Comstock Mining Inc.
P.O. Box 1118
Virginia City, NV 89440
ComstockMining.com
Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com
Zach Spencer
Director of External Relations
Tel (775) 847-5272 Ext.151
questions@comstockmining.com 

RCI Hospitality (RICK) – Strong Preliminary 2Q22 Sales

Wednesday, April 13, 2022

RCI Hospitality (RICK)
Strong Preliminary 2Q22 Sales

RCI Hospitality Holdings, Inc. through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and/or bar operations. The company also owns and operates a communication company serving the adult nightclubs industry. RCI’s operating business segments includes Nightclubs and Bombshells restaurants and bars. It operates nightclubs through the following brands: Rick’s Cabaret, Vivid Cabaret, Tootsie’s Cabaret, Club Onyx, and Jaguars Club. In the restaurants segment, the company is building a chain of Bombshells Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Club and Bombshells Sales. RCI reported preliminary second quarter 2022 sales for the nightclubs and Bombshells restaurants of $63.0 million. Same store sales for the quarter rose 9.0% and are up 14.8% for the first six months. This number does not include non-core operations. We projected full 2Q22 revenue of $65.3 million. We expect RCI to report full 2Q22 results by May 10th.

    Record March.  RCI achieved a record month in March, with sales of $24 million, a strong indicator of future normalized performance, in our view. The October acquisitions continue to improve, with the 11 clubs recovering to 95% of their March 2019 sales. Sales for northern clubs hit a twelve month high in March as COVID restrictions eased …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – Comtech Telecommunications Corp. to Participate in NobleCon18 Investor Conference



Comtech Telecommunications Corp. to Participate in NobleCon18 Investor Conference

Research, News, and Market Data on Comtech Telecommunications

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Apr. 13, 2022– 
April 13, 2022— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that it will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference at the 
Hard Rock Hotel & Casino
Hollywood, Florida on 
Wednesday, April 20, 2022 at 
4:30 pm EDT.

Comtech management will provide an overview of the Company and its business opportunities. There is also the opportunity to meet with management at our breakout sessions scheduled for 
Wednesday, April 20, 2022 at 
1:45 pm EDT and 
Thursday, April 21, 2022 at 
12:15 pm EDT.

A webcast of the presentation will be available on Comtech’s website at www.comtechtel.com and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website www.nobleconference.com and on Channelchek www.channelchek.com the investor portal created by Noble. The webcast is expected to be archived on Comtech’s website for a limited time following the event.

About Comtech

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions.

About Noble Capital Markets, Inc.

Noble Capital Markets (“Noble”) is a research driven investment bank that has supported small & microcap companies since 1984. As a 
FINRA and 
SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Comtech Investor Relations
Robert Samuels
631-962-7102
robert.samuels@comtech.com

Source: 
Comtech Telecommunications Corp.

Release – Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights



Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Research, News, and Market Data on Ceapro

 

– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in Company history

– Net profit of $2,842,000 for the full year of 2021 compared to a net profit of 1,856,000 in 2020, a year over year increase of 53%

 R&D activities focused on the development of avenanthramide pills for a Phase 1 study, on advancing the development of innovative delivery systems with new chemical complexes and on processing yeast beta glucan from various sources for the development of an immune booster and as a potential inhalable therapeutic for COVID-19

 Achieved record production levels despite COVID-19 pandemic situation, supply chain and transportation logistic challenges

EDMONTON, Alberta, April 13, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2021.

“We are thrilled with achievements made in 2021 on all fronts from production operations to research and development, allowing us to expand our pipeline to build a high value life sciences Company focused on immune and inflammation-based diseases. A 14% year over year increase in sales for our base business is absolutely remarkable especially during such a year marked by a continued COVID-19 pandemic, inflationary pressure, issues related to availability of inputs, persistently high logistical transportation costs and labour scarcity. Despite these challenges, our team worked tirelessly to meet strong demand for our products and deliver one of the best ever performances in the Company’s history. I thank everyone wholeheartedly for their resilience and dedication,” stated Gilles Gagnon, M.Sc., MBA, President and CEO, of Ceapro. “In addition to excellent financial and operational results, we had many key highlights over the course of the year and are committed to building on these achievements.”

2021 Corporate and Operational Highlights

Pipeline Development

Avenanthramides:

  • Announced expanded collaboration with Montreal Heart Institute (MHI) with new clinical study evaluating flagship product, avenanthramides, as a new potential pharmaceutical product. This Phase 1 safety and tolerability study will be led by renowned Dr. Jean-Claude Tardif. Published positive results from Ceapro’s previously conducted study evaluating anti-inflammatory properties of low doses of avenanthramides in exercise-induced inflammation paved the way for this clinical trial.
  • Agreement signed with Corealis to formulate 30mg and 240mg dosage pills to be used in Phase 1 study with MHI.
  • Completed physical characterization of avenanthramides and continued to monitor stability studies with new powder formulations.
  • Completed the Phase 1 study protocol which expects to enroll approximately 72 patients.

Oat Beta Glucan:

  • Completed pilot clinical trial evaluating oat beta glucan in patients with high cholesterol levels. While there were positive signals that beta glucan nutraceutical formulation may offer appreciable health benefits as indicated with approved Health Canada’s beta glucan monograph (Natural Product Division), the study did not achieve in a statistically significant manner the expected primary endpoint related to a decrease of low-density lipoproteins cholesterol when using Ceapro’s pill dosage form.
  • Announced research agreement with Boston-based Angiogenesis Foundation to assess in vivo bioefficacy of oat beta glucan and avenanthramides in angiogenesis, blood vessel repairs, and wounds to assess healing and tissue regeneration in various inflammation-based diseases and conditions like COVID-19 presenting damages of the lung blood vessels.

Yeast Beta Glucan (YBG)

  • Analyzed and screened YBG feedstock from numerous global suppliers to select ideal sources for best possible product.
  • Identified process conditions for YBG improving morphology of YBG processed using PGX Technology (PGX-YBG) to boost immunomodulating activity.
  • Further developed custom-shape formulations of PGX-YBG for oral administration.
  • Obtained further evidence confirming that PGX-YBG is suitable for lung inhalation.
  • Demonstrated, in vitro, that PGX processed YBG can prevent the activation of macrophages toward a pro-fibrotic phenotype which, according to experts in the field, is seen as a viable therapeutic strategy toward fibrotic disease.

    • PGX-YBG binds to specific receptors (Dectin 1) located on macrophages responsible for the cascade of immunomodulating events when activated.
    • McMaster’s research team discovered a new mechanism of action as per PGX-YBG’s ability to reprogram macrophages on its own.
  • Continuing PGX-YBG project with McMaster University to assess preclinical animal models to determine posology.
  • Initiated studies with a medical device manufacturer to assess aerosol/nebulizer device for inhalation of YBG.
  • Proved, using an in vitro study, that the Company’s PGX Technology maintains the integrity of the YBG molecular structure and enhances its microscopic morphology which leads to a boost in its immunomodulatory activity without generating proinflammatory reaction. Based on these attributes PGX-YBG is poised to become a key strategic asset for the Company.

New Chemical Complexes / Delivery Systems:

  • Announced the successful completion of a long-term research program conducted with University of Alberta. This screening program allowed Ceapro to retain the most promising products, such as PGX-alginate, and expand the PGX-processed products pipeline. Combination of alginate and YBG, leading to tunable PGX composites, are now viewed as the most promising products developed from this research program.
  • Pursued bioavailability studies with University of Alberta for new chemical complexes YBG-CoQ10, alginate-CoQ10 and the newly formed alginate-YBG-CoQ10. Results are expected in Q3 2022.

Technology:

  • Continued significant technical improvements of the existing PGX plant in Edmonton to develop equipment for the production of PGX-YBG for the purpose of generating material suitable for nutraceutical and lung delivery.
  • Ongoing engineering design in collaboration with experts in the field for designing and building a PGX processing commercial unit. Alginate and yeast beta glucan would be the first products to be processed at large scale level. Given regulatory requirements and to accelerate market entry, yeast beta glucan as a standalone and/or in combination with alginate will be developed at first as a nutraceutical/immune booster.
  • Pursued installment in Edmonton of a commercial scale unit for loading of bioactives onto PGX-processed biopolymers. This system allows loading of active pharmaceutical ingredients, like ibuprofen, onto thin soluble PGX alginate strips for wound healing or oral applications.
  • Continued projects with University of Alberta and McMaster University for the development of potential delivery systems for multiple applications in healthcare.

Bioprocessing Operations

  • Ceapro’s dedicated production team successfully responded to the growing market demand for the cosmeceutical base business by producing over 290 metric tons of active ingredients in 2021, a 20% increase over the previous year.
  • Received renewal of the Site License from the Health Canada Natural Product Directorate. This License enables the Company to manufacture, package, label, release and distribute final products.

Corporate

  • Fully repaid loan with Canadian Agricultural Adaptation Program (CAAP).
  • Effective December 31, 2021, the Company wound up Ceapro Technology Inc., Ceapro Active Ingredients Inc. and Ceapro BioEnergy Inc. into the Company and dissolved Ceapro USA Inc. JuventeDC Inc. remains the only active fully owned subsidiary of Ceapro Inc.
  • Announced expansion of a grant from National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to further develop the patented PGX Technology to increase its innovation capacity by designing the first pharmaceutical PGX processing unit along with bioactive impregnation and loading units.
  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

Subsequent to Year End

  • Signed a Supply and Distribution Agreement with Symrise securing the long-term sustainability of Ceapro’s base business.
  • Appointed Mr. Ronnie Miller, former President & CEO of Roche Canada for the last 22 years, to the Company’s Board of Directors.

Financial Highlights for the Fourth Quarter and the Full Year 2021 Ended December 31, 2021

  • Total sales of $3,562,000 for the fourth quarter of 2021 and $17,200,000 for the full year of 2021 compared to $2,706,000 and $15,100,000 for the comparative periods in 2020. These respective increases of 32% for Q4, 2021 and 14% for the full year 2021 were driven by volume sales increases in all of the Company’s primary products. The increase in revenue occurred despite being offset by a lower U.S. dollar relative to the Canadian dollar compared to the prior year, which negatively impacted revenue by approximately $1,358,000 for the full year 2021.
  • Net profit of $776,000 for the fourth quarter of 2021 and a net profit of $2,842,000 for the full year of 2021 compared to a net loss of $539,000 and a net profit of 1,856,000 for the comparative periods in 2020, a year over year increase of 53.1% for the full year 2021. These results reflect a full year of operations in one production site only as compared to year 2020 that was marked by the completion of the decommissioning of Leduc manufacturing site and the final integration of production operations in the Edmonton facility. Margins improved on an annual basis from 50% in 2020 to 56% in 2021.
  • Cash generated from operations of $3,510,000, for the full year 2021.
  • Positive working capital balance of $10,755,000 as of December 31, 2021.

“While the Company’s business has not been significantly impacted by the COVID-19 pandemic, management remains very vigilant in ensuring the highest level of safety for Ceapro’s employees. Depending on the evolution of this pandemic situation and assuming minimal supply chain disruptions, I strongly believe the prospects for the Company remain very strong for the upcoming year. We expect Ceapro’s cosmeceuticals base business to continue growing and provide positive cash flows to support the expansion to a new business model to a high value life science/biopharmaceutical company involved in nutraceuticals and pharmaceuticals. We then expect to further invest into R&D to initiate an early clinical trial with our newly developed pill of avenanthramide, to continue the development of new chemical complexes as potential delivery systems for bioactives and to emphasize our current efforts for the development and assessment of yeast beta glucan as immune booster and as potential inhalable therapeutics for lung fibrotic diseases including COVID 19 conditions,” added Mr. Gagnon.

“Additionally, results from bioavailability studies with new chemical complexes and results with yeast beta glucan as an immune booster will drive decisions for the magnitude of capital expenditures to be incurred for the building of a commercial scale unit for PGX Technology. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.


CEAPRO INC.        
Consolidated Balance Sheets        
         
         
  December 31,   December 31,  
  2021   2020  
  $   $  
         
ASSETS        
Current Assets        
Cash and cash equivalents 7,780,989   5,369,029  
Trade receivables 2,092,842   2,019,723  
Other receivables 45,850   102,224  
Inventories (note 3) 1,644,893   1,210,079  
Prepaid expenses and deposits 162,919   348,845  
         
Total Current Assets 11,727,493   9,049,900  
         
Non-Current Assets        
Investment tax credits receivable 766,629   607,700  
Deposits 79,539   82,124  
Licences (note 4) 15,551   18,514  
Property and equipment (note 5) 17,499,774   18,591,189  
Deferred tax assets (note 13 (b)) 439,063   874,304  
         
Total Non-Current Assets 18,800,556   20,173,831  
         
TOTAL ASSETS 30,528,049   29,223,731  
         
LIABILITIES AND EQUITY        
Current Liabilities        
Accounts payable and accrued liabilities 682,057   1,067,622  
Current portion of lease liabilities (note 6) 290,055   250,658  
Current portion of CAAP loan (note 8)   72,263  
         
Total Current Liabilities 972,112   1,390,543  
         
Non-Current Liabilities        
Long-term lease liabilities (note 6) 2,358,862   2,648,917  
Deferred tax liabilities (note 13 (b))   874,304  
         
Total Non-Current Liabilities 2,358,862   3,523,221  
         
TOTAL LIABILITIES 3,330,974   4,913,764  
         
Equity        
Share capital (note 7 (b)) 16,557,401   16,511,067  
Contributed surplus (note 7 (e)) 4,680,690   4,682,393  
Retained earnings 5,958,984   3,116,507  
         
Total Equity 27,197,075   24,309,967  
         
TOTAL LIABILITIES AND EQUITY 30,528,049   29,223,731  
         



CEAPRO INC.    
Consolidated Statements of Net Income and Comprehensive Income
     
   
   
  2021   2020  
Years Ended December 31, $   $  
     
Revenue (note 15) 17,195,329   15,121,282  
Cost of goods sold 7,506,036   7,498,996  
     
Gross margin 9,689,293   7,622,286  
     
Research and product development 3,779,102   1,881,883  
General and administration 3,239,672   3,282,754  
Sales and marketing 47,119   111,044  
Finance costs (note 11) 206,891   231,271  
     
Income from operations 2,416,509   2,115,334  
     
Other income (expense) (note 10) 202,281   (259,234 )
     
Income before tax 2,618,790   1,856,100  
     
Income taxes    
Current tax expense (note 13 (a)) 215,376    
Deferred tax benefit (note 13 (a)) (439,063 )  
     
Income tax benefit (223,687 )  
     
Total net income and comprehensive income for the year 2,842,477   1,856,100  
     
Net income per common share (note 20):    
Basic 0.04   0.02  
Diluted 0.04   0.02  
     
Weighted average number of common shares outstanding (note 20):    
Basic 77,673,804   77,594,629  
Diluted 78,590,706   78,143,033  
     



CEAPRO INC.    
Consolidated Statements of Cash Flows    
     
     
     
  2021   2020  
Years Ended December 31, $   $  
OPERATING ACTIVITIES    
Net income for the year 2,842,477   1,856,100  
Adjustments for items not involving cash    
Finance costs 140,270   153,538  
Transaction costs   1,108  
Depreciation and amortization 1,880,748   1,841,033  
Gain on disposal of equipment (5,000 )  
Accretion 11,621   21,625  
Income tax benefit (439,063 )  
Share-based payments 17,906   136,796  
  4,448,959   4,010,200  
CHANGES IN NON-CASH WORKING CAPITAL ITEMS    
Trade receivables (73,119 ) 1,639,818  
Other receivables 56,374   (55,412 )
Investment tax credits receivable (158,929 )  
Inventories (434,814 ) (541,074 )
Prepaid expenses and deposits 111,044   (88,839 )
Accounts payable and accrued liabilities relating to operating activities (298,765 ) (358,136 )
  (798,209 ) 596,357  
Net income for the year adjusted for non-cash and working capital items 3,650,750   4,606,557  
Interest paid (140,270 ) (153,538 )
CASH GENERATED FROM OPERATIONS 3,510,480   4,453,019  
INVESTING ACTIVITIES    
Purchase of property and equipment (689,431 ) (528,707 )
Purchase of leasehold improvements (19,472 ) (12,870 )
Proceeds from sale of equipment 5,000   353  
Deposits relating to the purchase of equipment   (77,467 )
Accounts payable and accrued liabilities relating to investing activities (86,800 ) 134,554  
CASH USED IN INVESTING ACTIVITIES (790,703 ) (484,137 )
FINANCING ACTIVITIES    
Stock options exercised 26,725   4,897  
Repayment of long-term debt   (112,973 )
Repayment of CAAP loan (83,884 ) (83,884 )
Repayment of lease liabilities (250,658 ) (265,088 )
CASH USED IN FINANCING ACTIVITIES (307,817 ) (457,048 )
Increase in cash and cash equivalents 2,411,960   3,511,834  
     
Cash and cash equivalents at beginning of the year 5,369,029   1,857,195  
     
Cash and cash equivalents at end of the year 7,780,989   5,369,029  


The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Issuer:
Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release 

Source: Ceapro Inc.

Allegiant Gold (AUXXF)(AUAU:CA) – Eastsides Expanding Resource Potential

Wednesday, April 13, 2022

Allegiant Gold (AUXXF)(AUAU:CA)
Eastside’s Expanding Resource Potential

Allegiant Gold is a mid-stage exploration stage company with 10 highly prospective projects in the southwest United States, including 7 projects in the State of Nevada. Allegiant’s flagship project is Eastside, a district-scale project in Nevada with inferred resources of 1.4 million gold and 8.8 million silver ounces of inferred resources and significant potential to add size and scale. The company’s shares trade on the TSX Venture Exchange under the ticker symbol “AUAU” and on the OTCQX under the ticker symbol “AUXXF.”

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Castle Zone Plan-of-Operations. Within the Eastside project area, Allegiant Gold commenced a Plan-of-Operations for the Castle Area to expand the permitted area from 5 acres to 1,648 acres. Castle is comprised of 130 claims encompassing an area of approximately 2,600 acres and includes the Berg, Blackrock, Boss, and Castle deposits.

    Upgrading resources.  The Castle Area hosts a pit-constrained inferred resource of 314,000 gold ounces averaging 0.49 grams of gold per tonne using a cut-off grade of 0.15 grams of gold per tonne. Allegiant’s goal is to expand the existing resource, upgrade resources from inferred to measured and indicated, along with conducting advanced metallurgical work leading up to an eventual preliminary …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

FINRA Says Only 14 Percent of Investors Think ESG Naturally Outperforms the Market


Image Credit: Scott (Flickr)


FINRA Survey Suggests Many ESG Investors May be Unaware Followers

 

Are ESG investors like airline passengers? A recent FINRA survey indicates, yes.

Perhaps you do this; when I get off the plane in a strange airport, I follow the crowd until I figure out where the baggage claim is. Sometimes, after a couple of minutes, I’ll ask someone that looks confident and was on my plane, where baggage is. I often find out they don’t know either; they have just been following others like me.

Survey of Investors About ESG

Gerri M. Walsh is the president of the FINRA Investor Education Foundation. Along with the NORC of the University of Chicago, they surveyed retail investors on their knowledge of Environmental, Social, and Governance (ESG) investing. Investing in funds and securities that have been designated as ESG has been a hot trend. Growth in ETFs alone has gone from $78 billion in 2019 to $378 billion earlier this year. This is a 485% increase in just over three years.

Since the trend toward investing in the ESG category is showing rampant growth, one might expect those among the herd know where they’re headed. This survey discovered instead that about one in four people believes the acronym stands for “earnings, stock, growth,” according to this well-formulated study.

 

Global Growth ESG ETF Assets from 2006 to February 2022 ($Billion)

 

Data: Statista


Survey Results

“Retail investors don’t understand ESG investing—only 9% say that they have ESG-related investments, and the familiarity with the concept is not as high or as broad as some of the coverage on the topic of ESG investing might suggest,” says Gerri Walsh.

Of the 1,228 investors surveyed, only 24% could correctly define ESG investing, and just 21% knew what the letters in ESG stood for. Walsh says this discovery is “both surprising and concerning.”

“If people are going to be thinking about these issues, we need to make sure that investors understand what we’re talking about, especially retail investors,” says FINRA’s president of investor education. “We need to make sure that people understand the terminology that’s being used, and what’s behind ESG investing.”

 

As uncovered by the survey, respondents said environmental factors were the least important when investing. The most important consideration respondents said are financial factors, including whether an investment has the potential for high returns, the related risk, and the associated fees. Perhaps the massive inflow into ESG funds has been performance-driven much more than the criteria followed by ESG funds.

The survey did, however, find that intentional ESG investors are highly motivated by ESG factors, especially the environment. When it comes to ESG funds’ performance, the greater part of investors (41%) believes that returns for companies that prioritize their impact on the environment and society will be the same as the overall market. Only 14% expect ESG investments to outperform the market.

Recent Performance Comparison

For the year 2021, a year strong year for stocks when the broader market was up 28.7% ($IVV), sustainable index funds produced similar returns. According to Morningstar data, the 13 ESG index funds available to U.S. investors that follow broad, diversified indexes of U.S. large-cap stocks posted gains ranging from 25.6% to 31.7%. Their average return was 29.2%, or 0.50% higher than the broad non-ESG specific measure.

Take-Away

There are all styles of investing. This is part of what makes markets. One conclusion that can be drawn from a recent collaboration by investment and research organizations is that ESG investors while growing in numbers, may not be intentionally investing in stocks of environmental, social, and corporate governance-minded companies. Perhaps this means investors were just following the amplified buzz around these investments. Or, it could hint that they were chasing returns that, in some cases, were running higher than the overall market.

What is now empirically shown is that only 14% believe that ESG will naturally outperform non-categorized investments. However, investing in ESG, whether intentional or not, has not been a bad move.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Issues Driving ESG Investing



What’s an ESG Score?





ESG Growing Pains Include Greenwashing



Are Small-Cap Stocks Smart Investments?

 

Sources

https://www.finra.org/about/executives/gerri-walsh

https://www.barrons.com/articles/esg-meaning-sustainable-investing-study-51649719876

https://www.morningstar.com/products/esg-investing

https://www.statista.com/topics/7463/esg-and-impact-investing/

 

Stay up to date. Follow us:

 

Release – Energy Fuels Hits Critical Mineral Trifecta in Rare Earths Uranium Vanadium

 


 


Energy Fuels Hits Critical Mineral ‘Trifecta’ in Rare Earths, Uranium & Vanadium; Now Performing Commercial-Scale Partial Rare Earth Separation

Research, News, and Market Data on Energy Fuels

 

Energy Fuels recently made commercial shipments of uranium, vanadium & advanced rare earth materials – all in a single week

LAKEWOOD, Colo.April 13, 2022 /CNW/ – Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (“Energy Fuels” or the “Company”) is pleased to announce that during the week of April 4, the Company’s White Mesa Mill located near Blanding, Utah (the “Mill“) made three (3) commercial shipments of three (3) critical mineral products. During that week, Energy Fuels shipped:

  1. Natural uranium concentrates (“U3O8“) to the Metropolis Works uranium conversion facility in Metropolis, Illinois for conversion into uranium hexafluoride which will be enriched and used as fuel for the production of clean, carbon-free nuclear energy;

  2. Vanadium pentoxide (“V2O5“) to the Bear Metallurgical Company in Butler, Pennsylvania for conversion to ferrovanadium (“FeV“) which will be sold into the steel and specialty alloys industries; and

  3. High-purity mixed rare earth element (“REE“) carbonate (“REE Carbonate“) to Neo Performance Materials’ (“Neo’s“) Silmet facility in Estonia for separation into advanced REE products. The REE Carbonate had undergone partial separation at the Mill using existing Mill facilities prior to its delivery to Silmet, which is the first commercial-scale REE separation to occur in the U.S. since at least the early-2000’s (to the Company’s knowledge).

This is the first time Energy Fuels, the Mill – and perhaps any facility in history – has accomplished such a feat. The Company believes it is clearly establishing itself as a “Clean Energy and Critical Mineral Hub” for the United States.

Rare Earth Elements:

The Company is pleased to announce that it has begun partial commercial-scale REE separations at its White Mesa Mill, located near Blanding, Utah (the “Mill“) utilizing existing Mill facilities. As a result, the Company is now producing a more advanced REE Carbonate than it did in 2021. The Company utilized an existing solvent extraction (“SX“) circuit at the Mill to remove most of the lanthanum (“La“) and produce an advanced cerium (“Ce“)-plus REE Carbonate. This product is roughly 32% – 34% neodymium-praseodymium (“NdPr“) and 1.8% terbium (“Tb“) and dysprosium (“Dy“) on a % TREO basis.

This is the first commercial-scale REE separation conducted by the Company, and to the Company’s knowledge, the first to occur in the U.S. since at least the early-2000’s. The successful integration of partial separations with existing Mill equipment and processes represents a significant advancement in Energy Fuels’ long-term plans of becoming a vertically integrated producer of advanced REE products. These separation processes also allow the Company to refine operating costs and optimize metallurgical and engineering designs for installation of a more advanced SX separation circuit at the Mill in the future. This most recent production campaign also further validates Energy Fuels’ monazite crack and leach process.

Energy Fuels continues to make rapid progress on restoring commercial REE capabilities to the United States. The Company is currently completing its latest campaign of REE Carbonate production (with partial La separation) from natural monazite sand concentrates. In July 2021, Energy Fuels began successfully extracting REEs from natural monazite utilizing a crack and leach process. The REE Carbonate that the Company has produced since July 2021 meets Neo’s commercial specifications, thereby allowing it to be fed directly into the separation process. Energy Fuels’ REE Carbonate is the most advanced REE material being produced at commercial quantities in the U.S. today, as it has been chemically altered, impurities have been removed, and it is ready for REE separation without further processing. The Company’s new REE Carbonate is even further advanced, as it has been partially separated. The Company is continuing to seek additional supplies of natural monazite sand to expand production.

The Company is also pleased to announce that it is making progress on its lab-scale REE separation pilot program. Lab-scale piloting began in 2021 and is ongoing. The Company has achieved production of a high-purity mixed NdPr oxide from its lab-scale pilot. A sample of NdPr oxide will be sent to Neo for further evaluation with the intent to sell this product as well as other separated oxides to Neo or others in the future. Through the operation of this pilot program, specific design criteria, as well as reagent costs, are being evaluated, which to date, are within initial expectations. REE separation piloting is expected to continue throughout the rest of 2022, which will also allow the Company to evaluate separation of the heavy REEs (samarium (“Sm“)-plus).

Energy Fuels has also formally engaged the French consulting firm, Carester SAS (“Carester“), to perform more detailed scoping, cost estimation, permitting support, technical support, and design for commercial “light” REE separation infrastructure at the Mill. The Company is currently preparing an application to the State of Utah, which it expects to submit in late 2022 or in early 2023. The Company plans to be in a position to initially produce up to 10,000 tonnes of total REE oxides (“TREO“) by 2025 or 2026. The preliminary, high-level scoping work Carester performed for Energy Fuels in 2021 estimated capital and operating costs to install and operate a “light” separation infrastructure at the Mill capable of producing 10,000 tonnes TREO per year, which are in line with the Company’s initial expectations. The Company’s expanded collaboration with Carester will include validation of these numbers. If confirmed, Energy Fuels expects to be among the lowest cost REE producers in the world, while also recovering uranium and possibly thorium. Energy Fuels is also evaluating the production of “heavy” REE oxides, including Dy and Tb, which could occur by 2027 or 2028.

Uranium:

The price of uranium has risen dramatically since Russia’s invasion of Ukraine. The spot price of natural uranium concentrates (“U3O8“) currently sits at $63.25 per pound, an increase of over 50% since December 31, 2021. Energy Fuels has been the largest producer of uranium in the United States for the past several years and has over 11.5 million pounds of annual uranium production capacity, more than any other U.S. company. As of December 31, 2021, the Company had roughly 700,000 pounds of U.S.-origin U3O8, produced by the Company in finished inventory and expects to produce an additional 100,000 to 120,000 pounds in 2022. All the Company’s current finished U.S. produced uranium inventory is at the two North American uranium conversion facilities. The Company also has additional significant stockpiled mineralized material at the Mill that can be processed relatively quickly for uranium recovery as required.

The Company has also observed a marked uptick in interest from nuclear utilities seeking long-term uranium supply, and is now actively engaged in pursuing selective long-term uranium sales contracts.

Vanadium:

Vanadium prices have also risen substantially this year. The mid-point spot price of vanadium oxide (“V2O5“) in Europe is currently $12.00 per pound, an increase of nearly 40% since the end of 2021. Energy Fuels has begun selectively selling some of its vanadium inventory in 2022 at increasing prices per pound of V2O5. The Company is continuing to ship V2Oto the Bear Metallurgical facility in Pennsylvania (“Bear Met“) for conversion to ferrovanadium (“FeV“) for sale into the steel and specialty alloy industries.

Mark S. Chalmers, President and CEO of Energy Fuels stated:  “I believe the week of April 4, 2022 will go down as one of the most important weeks in Company history. This week, our vision of Energy Fuels as ‘America’s Critical Mineral and Clean Energy Hub’ tangibly advanced, as our White Mesa Mill in Utah sent three shipments of advanced materials containing a total of fifteen critical elements, including the rare earth elements cerium, praseodymium, neodymium, samarium, europium, gadolinium, dysprosium, terbium, holmium, yttrium, erbium, thulium, ytterbium, and lutetium, along with uranium and vanadium, to downstream processing facilities. We sent a shipment of high-purity rare earth carbonate containing 32% – 34% NdPr to Silmet in Estonia, where it will be refined and processed into various advanced materials for use in permanent magnets used in electric vehicle (EV) motors and wind generation, batteries, electronics, defense applications, and other technologies. We sent a shipment of uranium concentrates to ConverDyn in Illinois for sale to U.S. nuclear utilities for the production of carbon-free nuclear energy, and further adding to Energy Fuels’ industry-leading finished U.S.-origin uranium inventory. And, we sent another truckload of vanadium to Bear Met in Pennsylvania for conversion into ferrovanadium for use in high-strength steel and other advanced and specialty alloys.

“I could not be more proud of what our team is doing at the White Mesa Mill on rare earths. It is hard to believe, but we are currently producing commercial-scale quantities of a rare earth material that is more advanced than any other company in the U.S. We even recently began commercial-scale rare earth separation in March using existing Mill facilities, the first time the United States has produced a separated rare earth product in a couple of decades. Keep in mind that we only announced our entry into the rare earth space in April 2020. Yet barely two years later, Energy Fuels is producing commercial quantities of advanced rare earth materials. We have been able to move at ‘lightning speed,’ because we have existing licenses, expertise, and infrastructure, along with dedication and hard work. We believe we are moving faster than any other company in the U.S. on restoring low-cost, domestic critical material supply chains. At Energy Fuels, we don’t just talk about restoring critical domestic supply chains. We innovate, invest, and work hard to actually do it, all to the highest environmental, human health, and human rights standards in the world.”

ABOUT ENERGY FUELS

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR“) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant, as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” Energy Fuels’ website is www.energyfuels.com.

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws in the United States and Canada. Forward-looking information may relate to future events or future performance of Energy Fuels. All statements in this release, other than statements of historical facts, with respect to Energy Fuels’ objectives and goals, as well as statements with respect to its beliefs, plans, objectives, expectations, anticipations, estimates, and intentions, are forward-looking information. Specific forward-looking statements in this discussion include, but are not limited to, the following: any expectation that the Company may establish itself as a Clean Energy and Critical Mineral Hub in the U.S; any expectation that the Company may be successful in becoming a vertically integrated producer of advanced REE products; any expectation that the Company may be successful in helping to restore commercial REE capabilities and critical supply chains in the U.S.; any expectation that the Company may be successful in securing additional supplies of natural monazite sand to expand production; any expectation that the Company may successfully permit and install a more advanced commercial separation circuit at the Mill in the future for the separation of light and/or heavy REEs and the timing of any such permitting and installation; any expectation as to future production levels of REE oxides; any expectation that the Company may be among the lowest-cost REE producers in the world; any expectation as to the amount of uranium the Company may produce in 2022; any expectation as to stockpiled mineralized material at the Mill that may be processed for the recovery of uranium and the timing of any such processing; any expectation that the Company may secure long-term uranium sales contracts at suitable uranium prices; any expectation as to future vanadium sales and the prices of such sales; and any expectation that the Company will be able to operate at the highest environmental, human health, and human rights standards in the world. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates” or “believes”, or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include risks associated with: technical difficulties; processing difficulties and upsets; licensing, permitting and regulatory delays; litigation risks; competition from others; and market factors, including future demand for and prices realized from the sale of uranium, vanadium and REEs. Forward-looking statements contained herein are made as of the date of this news release, and Energy Fuels disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Energy Fuels assumes no obligation to update the information in this communication, except as otherwise required by law.

SOURCE Energy Fuels Inc.

Synthetic Biology and a New Class of Antibiotics



Engineered Bacteria Could Help Protect “Good” Gut Microbes from Antibiotics

 

Anne Trafton | MIT
News Office

Antibiotics are life-saving drugs, but they can also harm the beneficial microbes that live in the human gut. Following antibiotic treatment, some patients are at risk of developing inflammation or opportunistic infections such as Clostridiodes difficile. Indiscriminate use of antibiotics on gut microbes can also contribute to the spread of resistance to the drugs.

In an effort to reduce those risks, MIT engineers have developed a new way to help protect the natural flora of the human digestive tract. They took a strain of bacteria that is safe for human consumption and engineered it to safely produce an enzyme that breaks down a class of antibiotics called beta-lactams. These include ampicillin, amoxicillin, and other commonly used drugs.

When this “living biotherapeutic” is given along with antibiotics, it protects the microbiota in the gut but allows the levels of antibiotics circulating in the bloodstream to remain high, the researchers found in a study of mice.

“This work shows that synthetic biology can be harnessed to create a new class of engineered therapeutics for reducing the adverse effects of antibiotics,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering, and the senior author of the new study.

Andres Cubillos-Ruiz PhD ’15, a research scientist at IMES and the Wyss Institute for Biologically Inspired Engineering at Harvard University, is the lead author of the paper, which appears today in Nature Biomedical Engineering. Other authors include MIT graduate students Miguel Alcantar and Pablo Cardenas, Wyss Institute staff scientist Nina Donghia, and Broad Institute research scientist Julian Avila-Pacheco.

Protecting the Gut

Over the past two decades, research has revealed that the microbes in the human gut play important roles in not only metabolism but also immune function and nervous system function.

“Throughout your life, these gut microbes assemble into a highly diverse community that accomplishes important functions in your body,” Cubillos-Ruiz says. “The problem comes when interventions such as medications or particular kinds of diets affect the composition of the microbiota and create an altered state, called dysbiosis. Some microbial groups disappear, and the metabolic activity of others increases. This unbalance can lead to various health issues.”

 

One major complication that can occur is infection of C. difficile, a microbe that commonly lives in the gut but doesn’t usually cause harm. When antibiotics kill off the strains that compete with C. difficile, however, these bacteria can take over and cause diarrhea and colitis. C. difficile infects about 500,000 people every year in the United States, and causes around 15,000 deaths.

Doctors sometimes prescribe probiotics (mixtures of beneficial bacteria) to people taking antibiotics, but those probiotics are usually also susceptible to antibiotics, and they don’t fully replicate the native microbiota found in the gut.

“Standard probiotics cannot compare to the diversity that the native microbes have,” Cubillos-Ruiz says. “They cannot accomplish the same functions as the native microbes that you have nurtured throughout your life.”

To protect the microbiota from antibiotics, the researchers decided to use modified bacteria. They engineered a strain of bacteria called Lactococcus lactis, which is normally used in cheese production, to deliver an enzyme that breaks down beta-lactam antibiotics. These drugs make up about 60 percent of the antibiotics prescribed in the United States.

When these bacteria are delivered orally, they transiently populate the intestines, where they secrete the enzyme, which is called beta-lactamase. This enzyme then breaks down antibiotics that reach the intestinal tract. When antibiotics are given orally, the drugs enter the bloodstream primarily from the stomach, so the drugs can still circulate in the body at high levels. This approach could also be used along with antibiotics that are injected, which also end up reaching the intestine. After their job is finished, the engineered bacteria are excreted through the digestive tract.

Using engineered bacteria that degrade antibiotics poses unique safety requirements: Beta-lactamase enzymes confer antibiotic resistance to harboring cells and their genes can readily spread between different bacteria. To address this, the researchers used a synthetic biology approach to recode the way the bacterium synthetizes the enzyme. They broke up the gene for beta-lactamase into two pieces, each of which encodes a fragment of the enzyme. These gene segments are located on different pieces of DNA, making it very unlikely that both gene segments would be transferred to another bacterial cell.

These beta-lactamase fragments are exported outside the cell where they reassemble, restoring the enzymatic function. Since the beta-lactamase is now free to diffuse in the surrounding environment, its activity becomes a “public good” for the gut bacterial communities. This prevents the engineered cells from gaining an advantage over the native gut microbes. 

“Our biocontainment strategy enables the delivery of antibiotic-degrading enzymes to the gut without the risk of horizontal gene transfer to other bacteria or the acquisition of an added competitive advantage by the live biotherapeutic,” Cubillos-Ruiz says.

Maintaining Microbial Diversity

To test their approach, the researchers gave the mice two oral doses of the engineered bacteria for every injection of ampicillin. The engineered bacteria made their way to the intestine and began releasing beta-lactamase. In those mice, the researchers found that the amount of ampicillin circulating the bloodstream was as high as that in mice who did not receive the engineered bacteria.

In the gut, mice that received engineered bacteria maintained a much higher level of microbial diversity compared to mice that received only antibiotics. In those mice, microbial diversity levels dropped dramatically after they received ampicillin. Furthermore, none of the mice that received the engineered bacteria developed opportunistic C. difficile infections, while all of the mice who received only antibiotics showed high levels of C. difficile in the gut.

“This is a strong demonstration that this approach can protect the gut microbiota, while preserving the efficacy of the antibiotic, as you’re not modifying the levels in the bloodstream,” Cubillos-Ruiz says.

The researchers also found that eliminating the evolutionary pressure of antibiotic treatment made it much less likely for the microbes of the gut to develop antibiotic resistance after treatment. In contrast, they did find many genes for antibiotic resistance in the microbes that survived in mice who received antibiotics but not the engineered bacteria. Those genes can be passed to harmful bacteria, worsening the problem of antibiotic resistance.

The researchers now plan to begin developing a version of the treatment that could be tested in people at high risk of developing acute diseases that stem from antibiotic-induced gut dysbiosis, and they hope that eventually, it could be used to protect anyone who needs to take antibiotics for infections outside the gut.

“If the antibiotic action is not needed in the gut, then you need to protect the microbiota. This is similar to when you get an X-ray, you wear a lead apron to protect the rest of your body from the ionizing radiation,” Cubillos-Ruiz says. “No previous intervention could offer this level of protection. With our new technology we can make antibiotics safer by preserving beneficial gut microbes and by reducing the chances of emergence of new antibiotic resistant variants.”

 

Suggested Reading



Opportunities in the Rapidly Growing Pain Management Sector



Stem-Cell Based Therapy for Alzheimer’s Disease





Why Stem Cell Stocks in 2021 Make Sense



Lithium Inflation and Availability Concerns Elon Musk

 

Stay up to date. Follow us:

 

Cocrystal Pharma Inc. (COCP) – First Results From Influenza Program Announced

Wednesday, April 13, 2022

Cocrystal Pharma Inc. (COCP)
First Results From Influenza Program Announced

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    First Data From Influenza Program Reported.  Cocrystal reported preliminary data from the Phase 1 clinical trial testing CC-42344, its oral antiviral for pandemic and seasonal influenza A. This is an orally administered drug that targets viral polymerase, blocking an early step in the viral lifecycle. The first two cohorts receiving single ascending doses of CC-42344 showed favorable safety and pharmacokinetic profiles.

    The Phase 1 Trial Continues.  The announcement was based on the first two cohorts treated with single doses of 100mg and 200mg and demonstrated safety with a favorable pharmacokinetic profile. To date, CC-42344 has shown strong bioavailablity, plasma levels that correlated with doses given, and a half-life that supports oral daily dosing. The trial has a target enrollment of 56 healthy adults and is …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.